Consistently, the inhibition of IDO in combination with anti-PD-L1 potentiated the therapeutic efficacy of the anti-HER2 antibody, completely reversing the suppressive effects of ADCP and the enhanced anti-tumor immunity [49]. This evidence concerns the gene CD274 and neoplasm.